Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 128-137

  Lorenz, Todd J ^a   Macdonald, Fraser ^a   Kitt, Michael M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Antibody; Eptifibatide; Immunogenicity; Peptide; Platelet

Indexed keywords

ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPTAPEPTIDE; IMMUNOGLOBULIN;

ANTIBODY COMBINING SITE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 0033011661     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88273-9     Document Type: Article

References (17)

1. 1. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation. 1995;91: 2151-2157.
2. 2. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
3. 3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. NEJM. 1994;330:956-961.
4. 4. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEJM. 1997; 336:1689-1696.
5. 5. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation. 1994;89:596-603.
6. 6. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
7. 7. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI. Circulation. 1997;95:846-854.
8. 8. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: A randomized, placebo-controlled, clinical trial. NEJM. 1998;339:436-443.
9. 9. Scarborough RM, Rose JW, Hsu MA, et al. Barbourin. A GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991; 266:9359-9362.
10. 10. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem. 1993;268:1066-1073.
11. 11. Harlow E, Lane D. In: Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory; 1988:56.
12. 12. Catty D. In: Rickwood D, Hames BD, eds. Antibodies: A Practical Approach. Vol. I. Washington, DC: IRL Press; 1996:7.
13. 13. Data on file. South San Francisco, California: COR Therapeutics, Inc.; 1990.
14. 14. Wong RS, Hancock RE. The effect of the length of a malarial epitope on its anti-genicity and immunogenicity in an epitope presentation system using the Pseudomonas aeruginosa outer membrane protein OprF as the carrier. FEMS Microbiol Lett. 1996;140:209-214.
15. 15. Chambers MA, Dougan G, Newman J, et al. Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions. J Virol. 1996;70:4045-4052.
16. 16. Kavun EM, Borisova EG, Kolibo DV, et al. Antigenic structure of the Pro-rich region 536-566 Bordatella pertussis pertactin (P.69). II: Analysis of peptide-specific antibodies. Biokhimiia. 1996;61: 1366-1374.
17. 17. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation. 1997;95:809-813.